Literature DB >> 20817853

Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry.

Derek Dube1, Kathryn L Schornberg, Charles J Shoemaker, Sue E Delos, Tzanko S Stantchev, Kathleen A Clouse, Christopher C Broder, Judith M White.   

Abstract

Ebolavirus is a hemorrhagic fever virus associated with high mortality. Although much has been learned about the viral lifecycle and pathogenesis, many questions remain about virus entry. We recently showed that binding of the receptor binding region (RBR) of the ebolavirus glycoprotein (GP) and infection by GP pseudovirions increase on cell adhesion independently of mRNA or protein synthesis. One model to explain these observations is that, on cell adhesion, an RBR binding partner translocates from an intracellular vesicle to the cell surface. Here, we provide evidence for this model by showing that suspension 293F cells contain an RBR binding site within a membrane-bound compartment associated with the trans-Golgi network and microtubule-organizing center. Consistently, trafficking of the RBR binding partner to the cell surface depends on microtubules, and the RBR binding partner is internalized when adherent cells are placed in suspension. Based on these observations, we reexamined the claim that lymphocytes, which are critical for ebolavirus pathogenesis, are refractory to infection because they lack an RBR binding partner. We found that both cultured and primary human lymphocytes (in suspension) contain an intracellular pool of an RBR binding partner. Moreover, we identified two adherent primate lymphocytic cell lines that bind RBR at their surface and strikingly, support GP-mediated entry and infection. In summary, our results reveal a mode of determining viral entry by a membrane-trafficking event that translocates an RBR binding partner to the cell surface, and they suggest that this process may be operative in cells important for ebolavirus pathogenesis (e.g., lymphocytes and macrophages).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20817853      PMCID: PMC2944755          DOI: 10.1073/pnas.1008509107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor.

Authors:  Jens H Kuhn; Sheli R Radoshitzky; Alexander C Guth; Kelly L Warfield; Wenhui Li; Martin J Vincent; Jonathan S Towner; Stuart T Nichol; Sina Bavari; Hyeryun Choe; M Javad Aman; Michael Farzan
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

2.  Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha.

Authors:  Akihito Yonezawa; Marielle Cavrois; Warner C Greene
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins.

Authors:  Kathryn L Schornberg; Charles J Shoemaker; Derek Dube; Michelle Y Abshire; Sue E Delos; Amy H Bouton; Judith M White
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-28       Impact factor: 11.205

4.  Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily.

Authors:  Lisa E Hensley; Howard A Young; Peter B Jahrling; Thomas W Geisbert
Journal:  Immunol Lett       Date:  2002-03-01       Impact factor: 3.685

Review 5.  Cell adhesion molecules and actin cytoskeleton at immune synapses and kinapses.

Authors:  Michael L Dustin
Journal:  Curr Opin Cell Biol       Date:  2007-10-17       Impact factor: 8.382

6.  Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Authors:  Kartik Chandran; Nancy J Sullivan; Ute Felbor; Sean P Whelan; James M Cunningham
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

7.  Arf6 and microtubules in adhesion-dependent trafficking of lipid rafts.

Authors:  Nagaraj Balasubramanian; David W Scott; J David Castle; James E Casanova; Martin Alexander Schwartz
Journal:  Nat Cell Biol       Date:  2007-11-18       Impact factor: 28.824

8.  Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells.

Authors:  Thomas W Geisbert; Howard A Young; Peter B Jahrling; Kelly J Davis; Tom Larsen; Elliott Kagan; Lisa E Hensley
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

9.  Kinetic analysis of secretory protein traffic and characterization of golgi to plasma membrane transport intermediates in living cells.

Authors:  K Hirschberg; C M Miller; J Ellenberg; J F Presley; E D Siggia; R D Phair; J Lippincott-Schwartz
Journal:  J Cell Biol       Date:  1998-12-14       Impact factor: 10.539

10.  Expression of Ebolavirus glycoprotein on the target cells enhances viral entry.

Authors:  Balaji Manicassamy; Lijun Rong
Journal:  Virol J       Date:  2009-06-08       Impact factor: 4.099

View more
  27 in total

1.  Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences.

Authors:  John Misasi; Kartik Chandran; Jin-Yi Yang; Bryden Considine; Claire Marie Filone; Marceline Côté; Nancy Sullivan; Giulia Fabozzi; Lisa Hensley; James Cunningham
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 3.  Filovirus entry into cells - new insights.

Authors:  Emily Happy Miller; Kartik Chandran
Journal:  Curr Opin Virol       Date:  2012-03-23       Impact factor: 7.090

4.  Ebola virus entry requires the host-programmed recognition of an intracellular receptor.

Authors:  Emily Happy Miller; Gregor Obernosterer; Matthijs Raaben; Andrew S Herbert; Maika S Deffieu; Anuja Krishnan; Esther Ndungo; Rohini G Sandesara; Jan E Carette; Ana I Kuehne; Gordon Ruthel; Suzanne R Pfeffer; John M Dye; Sean P Whelan; Thijn R Brummelkamp; Kartik Chandran
Journal:  EMBO J       Date:  2012-03-06       Impact factor: 11.598

5.  The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.

Authors:  Constantin Brinkmann; Inga Nehlmeier; Kerstin Walendy-Gnirß; Julia Nehls; Mariana González Hernández; Markus Hoffmann; Xiangguo Qiu; Ayato Takada; Michael Schindler; Stefan Pöhlmann
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

6.  Characterization of the receptor-binding domain of Ebola glycoprotein in viral entry.

Authors:  Jizhen Wang; Balaji Manicassamy; Michael Caffrey; Lijun Rong
Journal:  Virol Sin       Date:  2011-06-12       Impact factor: 4.327

7.  Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate.

Authors:  Andres Chang; Cyril Masante; Ursula J Buchholz; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

8.  Repurposing Quinacrine against Ebola Virus Infection In Vivo.

Authors:  Thomas R Lane; Jason E Comer; Alexander N Freiberg; Peter B Madrid; Sean Ekins
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

9.  Ebola virus exploits a monocyte differentiation program to promote its entry.

Authors:  Osvaldo Martinez; Joshua C Johnson; Anna Honko; Benjamin Yen; Reed S Shabman; Lisa E Hensley; Gene G Olinger; Christopher F Basler
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

10.  Understanding of Zaire ebolavirus-human protein interaction for drug repurposing.

Authors:  Mathavan Muthaiyan; Shilpa Sri Pushan; Leimarembi Devi Naorem; Amouda Venkatesan
Journal:  Virusdisease       Date:  2020-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.